Fair market value vs. commercial reasonableness: two tests a directorship has to pass

When a hospital pays a referring physician to direct a department, the arrangement has two standards to satisfy, and they get conflated constantly. "The rate is market" answers one of them. Whether the hospital should be buying those hours at all is the other, and no benchmark on earth can answer it.

This piece walks through the distinction the way appraisers and compliance teams generally frame it: what each test asks, why both exist, and where market data helps, so the professional reading a directorship file knows which question each piece of evidence speaks to.

Educational note

This article explains how these concepts are generally understood. It is not legal, compliance, or valuation advice, and it doesn't address any specific arrangement. For a real directorship, the fair market value opinion belongs with a qualified appraiser and the regulatory analysis with counsel.

Two different questions, often conflated

Fair market value is a pricing question. Is the compensation consistent with what the market would pay for these services in an arm's-length transaction, without regard to referrals between the parties? It's about the rate: the dollars against the duties, the hours, and the qualifications the role requires.

Commercial reasonableness is a purpose question. Does the arrangement make sense for the facility on its own terms: is the role needed, are the hours sensible, is the structure sound, even if no referrals ever flowed? It's about the arrangement itself, and it would still have to be answered if the price were zero.

Because the questions are different, an arrangement can pass one and fail the other. A hospital paying a market rate to a fourth co-director of a department that needs one is fine on FMV and exposed on commercial reasonableness; nothing about the rate fixes a role with no business purpose. A genuinely needed ICU directorship paying double the market fails in the other direction. Neither test substitutes for the other, and a file that documents only one has covered half the ground.

The FMV question The commercial-reasonableness question Asks Is the pay consistent with the market, referrals aside? Does the arrangement make sense, referrals aside? About The rate The role Evidence Benchmarks, surveys, cost-report data, documented hours Duty descriptions, staffing plans, board documentation Answered by Qualified appraiser Management and counsel Market data's job Informs the range Not applicable

Why both matter

Both standards come out of the federal fraud-and-abuse framework, at a general level: the Stark Law, which governs compensation arrangements between hospitals and referring physicians and expects them to be consistent with fair market value, commercially reasonable, and not determined in a manner that takes into account the volume or value of referrals; and the Anti-Kickback Statute, which is intent-based and reaches remuneration intended to induce referrals. Directorships sit squarely in this territory because the director is usually a referring physician, which is exactly why these arrangements get papered, benchmarked, and audited so heavily.

Two points from the 2021 Stark final rule are worth knowing in general terms. CMS formally defined commercial reasonableness for the first time, and clarified that an arrangement can be commercially reasonable even if it isn't profitable for one of the parties; the test is whether it furthers a legitimate business purpose, judged on the facts. And on FMV, CMS anchored the definition to the general market value of the transaction itself, not to the parties' referral relationship. The consequences of getting either wrong (repayment obligations, penalties, False Claims Act exposure) are the reason this distinction is more than semantics.

Where market data fits, and where it doesn't

Market data informs the FMV range. Knowing that individual hospital directorships have a median implied rate of $175 an hour with the middle half between $141 and $235, and that specialty moves the number more than anything else, is exactly the kind of evidence an FMV analysis is built on. It locates an arrangement in the market: inside the middle half, in a tail, or off the map.

Two hard limits, and the regulator drew the first one itself. CMS declined to treat any survey range as automatic FMV; in its own framing, compensation at the median may not be fair market value while compensation above the 75th percentile may be, depending on the facts. So the benchmark locates; it does not grade. A rate inside the middle half is a data point in favor, not a conclusion, and a rate in the tail is a question, not a verdict.

The benchmark locates; it does not grade. A rate inside the middle half is a data point in favor, not a conclusion.

The second limit is bigger: market data says nothing about commercial reasonableness. No dataset can tell you whether this facility needs 400 hours of oversight in this department, whether the duties overlap with an existing role, or whether three co-directors are two too many. That evidence lives in duty descriptions, staffing plans, committee calendars, and board documentation, not in a rate table.

How appraisers use a benchmark in an FMV analysis

As one input among several, roughly in this order: convert the stipend to an implied hourly rate, select the cohort by specialty and scope, weigh more than one source (survey data and cost-report data measure the market differently, and agreement between them is worth more than either alone), then read the market position against the specific duties, required qualifications, and documented time. The opinion comes last and rests on the whole record.

What a good comp set contributes to that file is checkability. The Medical Director tool supplies market data built from public Medicare cost reports, inspectable line by line with sample sizes disclosed, which means the data layer of an FMV analysis can be verified by anyone who challenges it. The judgment layer can't be outsourced to it, by design.

What the benchmark can't do for you

Three things, and they're the same three whether the data comes from us or anyone else.

• It can't render the FMV opinion — That is a professional judgment on the facts of the specific arrangement.
• It can't establish commercial reasonableness — That case is made from the facility's own business record.
• It can't substitute for counsel — How the regulatory framework applies to an arrangement is a legal question.

The division of labor that works: market data supplies the range, the appraiser supplies the FMV opinion, management and counsel own the commercial-reasonableness record. Directorship arrangements that hold up tend to have all three, in writing. For the market half of that equation, start with what hospitals pay medical directors.

Sources and method

• Market figures — Median implied rate $175/hr; middle half $141 to $235 (individual directorships, n = 9,608)
• Source — CMS Form 2552-10 Worksheet A-8-2, Medicare hospital cost reports, FY2024–2025
• Regulatory content — Stark and the Anti-Kickback Statute described at a general level; 2021 Stark final rule points stated as background, not guidance
• Scope — Educational. No specific arrangement is analyzed, and nothing here is legal, compliance, or valuation advice

Full methodology and limitations

Disclaimer

This article is a market-data benchmarking resource derived from publicly available Medicare hospital cost reports. It does not provide, and must not be relied upon as, a fair market value determination, valuation opinion, appraisal, or legal, tax, or compliance advice. The opinion of value for any specific arrangement remains the professional judgment of a qualified appraiser.